Unraveling a causal relationship between GLP-1 agonists and AP is intricate, particularly as patients with T2DM are already three times more predisposed to pancreatitis compared to their non-diabetic counterparts (Girman et al., 2010). The gene discussed is GCG; the disease is alkaline phosphatase measurement.